Trial Profile
A Phase 1 Study Of SU011248 [sunitinib; Sutent] And Gemcitabine [Gemzar] In Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2010
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 20 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from 1 Sep 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.